CN108576346A - A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar reducing blood lipid - Google Patents
A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar reducing blood lipid Download PDFInfo
- Publication number
- CN108576346A CN108576346A CN201810287322.7A CN201810287322A CN108576346A CN 108576346 A CN108576346 A CN 108576346A CN 201810287322 A CN201810287322 A CN 201810287322A CN 108576346 A CN108576346 A CN 108576346A
- Authority
- CN
- China
- Prior art keywords
- parts
- inonotus obliquus
- blood lipid
- pressed candy
- reducing blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000414067 Inonotus obliquus Species 0.000 title claims abstract description 32
- 210000004369 blood Anatomy 0.000 title claims abstract description 26
- 239000008280 blood Substances 0.000 title claims abstract description 26
- 230000001603 reducing effect Effects 0.000 title claims abstract description 26
- 150000002632 lipids Chemical class 0.000 title claims abstract description 16
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 14
- 235000009508 confectionery Nutrition 0.000 title claims abstract description 12
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 14
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 14
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 10
- 229940026314 red yeast rice Drugs 0.000 claims abstract description 10
- 235000010523 Cicer arietinum Nutrition 0.000 claims abstract description 9
- 244000045195 Cicer arietinum Species 0.000 claims abstract description 9
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000013557 nattō Nutrition 0.000 claims abstract description 9
- 241000208688 Eucommia Species 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 6
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000811 xylitol Substances 0.000 claims abstract description 6
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 6
- 229960002675 xylitol Drugs 0.000 claims abstract description 6
- 235000010447 xylitol Nutrition 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 2
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
- 210000002221 olecranon process Anatomy 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 13
- 230000002218 hypoglycaemic effect Effects 0.000 abstract description 10
- 230000003712 anti-aging effect Effects 0.000 abstract description 6
- 230000002929 anti-fatigue Effects 0.000 abstract description 6
- 230000006837 decompression Effects 0.000 abstract description 6
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 5
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 230000036772 blood pressure Effects 0.000 description 9
- 241000229143 Hippophae Species 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- -1 daizeol Chemical compound 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 235000018185 Betula X alpestris Nutrition 0.000 description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 description 2
- 241000747105 Fuscoporia Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 150000003648 triterpenes Chemical class 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- CQIUKKVOEOPUDV-UHFFFAOYSA-N citrinine Natural products OC1=C(C(O)=O)C(=O)C(C)=C2C(C)C(C)OC=C21 CQIUKKVOEOPUDV-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical group 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical group 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to field of health care food, can anticancer reducing pressure and sugar reducing blood lipid Inonotus obliquus pressed candy.Trade name is：Inonotus obliquus pressed candy.Its active ingredient is prepared from the following raw materials in parts by weight：8 12 parts of L-arabinose, 8 12 parts of xylitol, 15 22 parts of Inonotus obliquus, 8 12 parts of pueraria lobata, 8 12 parts of chick-pea, 8 12 parts of sea-buckthorn, 8 12 parts of eucommia Bark male flower, 8 12 parts of natto, 8 12 parts of red yeast rice.Prescription is prepared simply, at low cost.Formula has edibility, has no toxic side effect, safe and reliable.To anticancer, decompression, hypoglycemic, reducing blood lipid, anti-aging, it is antifatigue have booster action, can enhance body's immunity, prevent cardiovascular and cerebrovascular disease.
Description
Technical field
The present invention relates to field of health care food, can anticancer reducing pressure and sugar reducing blood lipid Inonotus obliquus pressed candy.Commodity
It is entitled：Inonotus obliquus pressed candy.
Background technology
In the prior art, in recent years, solid beverage industry steps into fast-developing channel, enterprise inside the circle's quantity and row
Industry production and marketing scale constantly expands.Solid beverage because of numerous in variety, unique flavor, using plant extracts as primary raw material, be easy to deposit
It puts and receives consumers, especially those have nutrition, health-care assistance effect rich in vitamin, minerals, Chinese medicine etc.
Nutrition needed for body metabolism can be replenished in time in the solid beverage of ingredient, more become the good companion being be unable to do without during many life are lived
Companion.National publication integration of drinking and medicinal herbs article, solid beverage can add Chinese medicine, for making health food, meet the people day
The tonic of beneficial demand, solid beverage have welcome development opportunity.
Invention content
The object of the present invention is to provide a kind of prescription is simple, there is nutrition and health care, anticancer, blood pressure lowering, hypoglycemic, reducing blood lipid
The Inonotus obliquus pressed candy of effect.
Technical solution of the invention：A kind of Inonotus obliquus pressed candy of energy anticancer decompression reducing blood sugar and blood fat,
It is characterized in that its active ingredient is prepared from the following raw materials in parts by weight：L -8-12 parts of arabinose, 8-12 parts of xylitol, birch
Brown pore fungi 15-22 parts, it is 8-12 parts of pueraria lobata, 8-12 parts of chick-pea, 8-12 parts of sea-buckthorn, 8-12 parts of eucommia Bark male flower, 8-12 parts of natto, red
It is 8-12 parts bent.Inonotus obliquus, pueraria lobata, chick-pea, eucommia Bark male flower, red yeast rice, L-arabinose synergistic effect can enhance in prescription
The effect of blood pressure lowering, hypoglycemic, reducing blood lipid, chick-pea, pueraria lobata synergistic effect can it is anti-oxidant, improve ability of learning and memory, Du
Zhong Xionghua, red yeast rice, sea-buckthorn interaction can enhance body's immunity, and pueraria lobata, natto synergistic effect can adjust heart and brain blood
Pipe function.
It is preferably but not limited to：A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar reducing blood lipid, it is characterised in that by
The raw material of following parts by weight is made：10 parts of L-arabinose, 10 parts of xylitol, 20 parts of Inonotus obliquus, 10 parts of pueraria lobata, olecranon
10 parts of beans, 10 parts of sea-buckthorn, 10 parts of eucommia Bark male flower, 10 parts of natto, 10 parts of red yeast rice.
Preparation method：By above-mentioned raw materials through despecking, cleaning, extraction, drying and crushing, particle is made after be pressed into tablet.
The ingredient that main pharmacological is played in Inonotus obliquus is lanosterol type triterpenes, Inonotus obliquus alcohol, Inonotus obliquus
Element and lignin.With kinds of tumors such as resistance liver cancer, gastric cancer, lung cancer, cervical carcinoma, breast cancer, cutaneum carcinoma, the carcinoma of the rectum, lymphs
Cell and AIDS virus resisting, anti-infective, treatment diabetes, blood pressure lowering adjust blood fat, anti-body aging, strengthen immunity
Equal pharmacological actions.
Pueraria lobata is the dry root of legume pueraria lobata.Main component be Puerarin, daizeol, arachidic acid, amino acid,
Protein, multivitamin, organic calcium etc. can expand coronary artery blood vessel and improve myocardial ischemia-anoxemia state, decompression, inhibit blood
Platelet aggregation anti-arrhythmia, improves brain blood circulation, is anti-oxidant, hypoglycemic, improving learning and memory function.Effect expelling pathogenic factors from muscles and skin brings down a fever,
Shengyang Zhixie.
Chick-pea main component is triterpenoid saponin and triterpenes, osajin, flavanol compound, fatty acid.Blood can drop
Fat, anti-aging, inhibits cytosis, improving studing ability, the growth for inhibiting tumour cell at hypoglycemic, norcholesterol.
Sea-buckthorn main component is vitamins, flavonoids etc., can promote hematopoietic growth, lipid-loweringing, to hepatic injury
Protective effect, enhancing immune function, radioresistance, scavenging activated oxygen effect, experiment show that seabuckthorn fruit powder can improve hardy
Cold, endurance, the ability of anti anoxia.
Eucommia Bark male flower main component is amino acid and isoquercitrin etc., can resisting stress, antifatigue, reducing blood lipid, enhancing exempt from
Epidemic disease function.
Natto main component is saponin, and isoflavones, unsaturated fatty acid, lecithin etc. being capable of thrombus, effectively prevention
With improvement cardiovascular and cerebrovascular disease, antifatigue, anti-aging, prevention senile dementia, gastrointestinal function is adjusted.
Red yeast rice main component is monascorubin, Lovastatin, citrinin etc., can lowering blood pressure and blood fat, enhancing it is non-specific
Property immune function.
L-arabinose can inhibit sucrose absorb, inhibit body fat accumulation, can be used for prevent obesity, hypertension,
The diseases such as hyperlipidemia.
Inonotus obliquus, pueraria lobata, chick-pea, eucommia Bark male flower, red yeast rice, L-arabinose synergistic effect can enhance drop in prescription
The effect of blood pressure, hypoglycemic, reducing blood lipid, chick-pea, pueraria lobata synergistic effect can it is anti-oxidant, improve ability of learning and memory, Cortex Eucommiae
Male flower, red yeast rice, sea-buckthorn interaction can enhance body's immunity, and pueraria lobata, natto synergistic effect can adjust cardiovascular and cerebrovascular.
Dosage form of the present invention is without being limited thereto, may also be fabricated which that granule, powder, capsule or other field of health care food are routinely made
Agent.
Effect：Anticancer adjuvant, decompression, hypoglycemic, reducing blood lipid, anti-aging, antifatigue, prevention cardiovascular and cerebrovascular disease.
Usage and dosage：By taking tablet as an example, it is proposed that per consumption per day 6-10 pieces.
Target user：To anticancer, decompression, hypoglycemic, reducing blood lipid, anti-aging, antifatigue and enhancing body's immunity, prevent
Cardiovascular and cerebrovascular disease has the crowd of demand.
It is an advantage of the invention that：1. prescription is prepared simply, at low cost.2. formula have edibility, have no toxic side effect, safety, can
It leans on.3. pair anticancer, decompression, hypoglycemic, reducing blood lipid, anti-aging, it is antifatigue have booster action, body's immunity can be enhanced, prevent
Cardiovascular and cerebrovascular disease.4, the crowd through 120 blood pressures of cumulative statistics, blood glucose, Hyperlipidemia takes, effective percentage 100%.
Embodiments of the present invention are described in further detail below in conjunction with embodiment.
Specific implementation mode
Embodiment 1
A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar reducing blood lipid, it is characterised in that by the raw material of following parts by weight
It is made：10 parts of L-arabinose, 10 parts of xylitol, 20 parts of Inonotus obliquus, 10 parts of pueraria lobata, 10 parts of chick-pea, 10 parts of sea-buckthorn, Du
10 parts of Zhong Xionghua, 10 parts of natto, 10 parts of red yeast rice.
Test example
1. the experimental research achievements of pair Inonotus obliquus
Observation finds that Fuscoporia obliqua polysaccharide extract, up to 39. 39 %, can improve mouse to liver cancer mouse HepA tumors inhibiting rate
Immune function obviously increases the activity of immune organ weight and serum L22, enhances monocyte phagocytic function；Gastric cancer, birch are brown
Linteus extract has Inhibit proliferaton effect, inducing apoptosis of tumour cell to human gastric cancer BGC2823 cell strains, and shows output
Effect relationship；Lung cancer, influence of the observation Inonotus obliquus water decoction to patients with lung cancer intestinal flora, it is found that Inonotus obliquus group compares simplification
Bifidobacteria is obviously more in the enteron aisle for the treatment of group, and coccus quantity is few；Cervical carcinoma, the water extract of Inonotus obliquus can make one uterine neck
The protein quantity and mitotic index of cancer cell (HeLaS3) decline, and improve the cell number of mitosis metaphase, influence
Cell cycle influences the metabolism of cell simultaneously to the mitosis of interference cell；Other tumours, golden light etc. are observed
Fuscoporia obliqua polysaccharide has apparent inhibiting effect, the inhibition tumour rate point of large and small dosage group to the growth of small S180 sarcoma of rats
It Wei not 56. 31 % and 44. 34 %
The triterpene compound and steroids of Inonotus obliquus have the work for improving blood circulation, adjusting blood pressure, reducing cholesterolemia
With clinical observation to Inonotus obliquus has certain effect to prevention and treatment hypertension, can reduce the blood pressure of hypertensive patient simultaneously
Mitigate symptom, has shared coordinative role with conventional buck medicine, kept blood pressure more easy to control and steady.
Inonotus obliquus, inonotus obliquus sclerotium and mycelial polysaccharide crude extract, have drop to alloxan diabetes mouse
Blood glucose act on, and in three's hypoglycemic effect without significant difference clinically diabetic using Inonotus obliquus treatment after it is complete
Blood viscosity, plasma viscosity, fibrinogen, packed cell volume, erythrocyte aggregation index before treatment than being substantially reduced.
54 primary hyperlipidemia patients are observed, find serum of the patient using Inonotus obliquus water decoction after 4 weeks
Total cholesterol (TC) and triglycerides (TG) are significantly lower than control group, prove that it has the function of adjusting blood fat.
It is described above, only specific implementation mode of the invention, various illustrations are not to the substantive content structure of the present invention
At limitation.
Claims (2)
1. a kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar reducing blood lipid, it is characterised in that its active ingredient is by following heavy
The raw material of amount number is made：L -8-12 parts of arabinose, 8-12 parts of xylitol, 15-22 parts of Inonotus obliquus, 8-12 parts of pueraria lobata, hawk
8-12 parts of garbanzo, 8-12 parts of sea-buckthorn, 8-12 parts of eucommia Bark male flower, 8-12 parts of natto, 8-12 parts of red yeast rice.
2. the Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar reducing blood lipid described in accordance with the claim 1, it is characterised in that by
The raw material of following parts by weight is made：10 parts of L-arabinose, 10 parts of xylitol, 20 parts of Inonotus obliquus, 10 parts of pueraria lobata, olecranon
10 parts of beans, 10 parts of sea-buckthorn, 10 parts of eucommia Bark male flower, 10 parts of natto, 10 parts of red yeast rice.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810287322.7A CN108576346A (en) | 2018-03-30 | 2018-03-30 | A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar reducing blood lipid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810287322.7A CN108576346A (en) | 2018-03-30 | 2018-03-30 | A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar reducing blood lipid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108576346A true CN108576346A (en) | 2018-09-28 |
Family
ID=63625139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810287322.7A Pending CN108576346A (en) | 2018-03-30 | 2018-03-30 | A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar reducing blood lipid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108576346A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112998175A (en) * | 2021-03-23 | 2021-06-22 | 河南可有福生物科技有限公司 | Earthworm protein sea cucumber peptide composite polypeptide solid beverage |
| CN114177247A (en) * | 2021-12-17 | 2022-03-15 | 广东长昊药业股份有限公司 | Anticancer blood sugar-controlling inonotus obliquus pure powder tablet and preparation method and application thereof |
| CN118490740A (en) * | 2024-07-11 | 2024-08-16 | 广州滋得洛夫生物科技有限责任公司 | Inonotus obliquus composition with increased effects of reducing blood sugar, blood pressure and uric acid and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101223928A (en) * | 2008-01-29 | 2008-07-23 | 张康健 | Eucommia Bark male flower instant tea and preparing method thereof |
| CN102599512A (en) * | 2012-03-26 | 2012-07-25 | 中国科学院新疆理化技术研究所 | Sea buckthorn nutrition powder and preparation method thereof |
| CN106819750A (en) * | 2017-01-11 | 2017-06-13 | 大连雅威特生物技术股份有限公司 | Hypoglycemic solid beverage of a kind of aided blood pressure-lowering and preparation method thereof |
| CN107080250A (en) * | 2017-03-30 | 2017-08-22 | 北京林业大学 | A kind of composition of auxiliary hyperglycemic, beverage and preparation method thereof |
| CN107156623A (en) * | 2017-05-27 | 2017-09-15 | 周勇 | A kind of composite cereal mixture and preparation method thereof |
| CN107772432A (en) * | 2016-08-25 | 2018-03-09 | 胡彦峰 | A kind of food using CHAGA as major ingredient |
-
2018
- 2018-03-30 CN CN201810287322.7A patent/CN108576346A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101223928A (en) * | 2008-01-29 | 2008-07-23 | 张康健 | Eucommia Bark male flower instant tea and preparing method thereof |
| CN102599512A (en) * | 2012-03-26 | 2012-07-25 | 中国科学院新疆理化技术研究所 | Sea buckthorn nutrition powder and preparation method thereof |
| CN107772432A (en) * | 2016-08-25 | 2018-03-09 | 胡彦峰 | A kind of food using CHAGA as major ingredient |
| CN106819750A (en) * | 2017-01-11 | 2017-06-13 | 大连雅威特生物技术股份有限公司 | Hypoglycemic solid beverage of a kind of aided blood pressure-lowering and preparation method thereof |
| CN107080250A (en) * | 2017-03-30 | 2017-08-22 | 北京林业大学 | A kind of composition of auxiliary hyperglycemic, beverage and preparation method thereof |
| CN107156623A (en) * | 2017-05-27 | 2017-09-15 | 周勇 | A kind of composite cereal mixture and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112998175A (en) * | 2021-03-23 | 2021-06-22 | 河南可有福生物科技有限公司 | Earthworm protein sea cucumber peptide composite polypeptide solid beverage |
| CN114177247A (en) * | 2021-12-17 | 2022-03-15 | 广东长昊药业股份有限公司 | Anticancer blood sugar-controlling inonotus obliquus pure powder tablet and preparation method and application thereof |
| CN118490740A (en) * | 2024-07-11 | 2024-08-16 | 广州滋得洛夫生物科技有限责任公司 | Inonotus obliquus composition with increased effects of reducing blood sugar, blood pressure and uric acid and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102919836B (en) | Health-care product capable of reducing blood glucose, releasing pressure, reducing lipid, relaxing bowel, beautifying, losing weight and resisting fatigue and production process thereof | |
| KR101160943B1 (en) | Health functional foods compositions for the prevention and amelioration of cancer containing the mixed extract of Phellinus linteus mycelium and cultured Panax Ginseng Cameyer as an active ingredient | |
| CN102827750A (en) | Maca health care liquor for improving organism immunity and sexuality | |
| JP6404339B2 (en) | Composition having function of alleviating premenstrual syndrome and menstrual pain | |
| CN101253903B (en) | Health food with fat-reducing function and its preparation | |
| Zhao et al. | Polygonati Rhizoma with the homology of medicine and food: A review of ethnopharmacology, botany, phytochemistry, pharmacology and applications | |
| CN101579120A (en) | Nutritional food with weight-losing function and preparation method thereof | |
| CN108576346A (en) | A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar reducing blood lipid | |
| US20180296615A1 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
| CN102726557A (en) | Food possessing auxiliary hypolipidemic function | |
| CN108813501A (en) | With the relieving cough and reducing sputum health honey paste relievingd asthma and adjust function of human body of clearing heat and moistening lung | |
| KR102112599B1 (en) | Anti-obesity composition comprising Punica granatum and Citrus junos extract as effective component | |
| KR102080410B1 (en) | Composition for Preventing, Treating or Improving of Andropause Syndrome Comprising Elderberry Extracts | |
| EP3025721B1 (en) | Pharmaceutical composition for preventing or treating asthma comprising pistacia weinmannifolia j. poiss. ex franch extract or fraction thereof | |
| CN102552562A (en) | Formula for health care medicine capable of enhancing immunity and delaying aging | |
| CN105433382A (en) | Peruvian ginseng composition as well as preparation method and application thereof | |
| CN101496604A (en) | Nutrient foodstuffs with function for reducing blood fat and preparation method thereof | |
| KR20150002048A (en) | A composition for preventing wrinkle of skin and anti aging of skin | |
| CN108477372A (en) | A kind of Inonotus obliquus pressed candy of energy anticancer reducing pressure and sugar anti-aging tranquilizing effect | |
| CN103181557A (en) | Nutritious food with slimming function and preparation method thereof | |
| US10383904B2 (en) | Composition for improving health and quality of life of women containing ginseng berry extract | |
| CN108813500B (en) | Health-preserving honey paste with effects of tonifying middle-jiao and Qi, nourishing blood and soothing nerves and regulating human body functions | |
| CN105638961A (en) | Dark green tea composition with ramie leaves and preparation method thereof | |
| CN105106721A (en) | Health product with efficacy of reducing blood sugar | |
| CN102138593A (en) | Formula of lotus leaf fat eliminating and body building tea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180928 |